Gilead Sciences has acquired Keymed Biosciences for an undisclosed amount, marking a strategic expansion of its therapeutic capabilities. Keymed Biosciences Inc. (HKEX: 02162) is a company focused on urgent unmet clinical needs, committed to providing high-quality, affordable, innovative therapies for patients in China and overseas. The acquisition brings Keymed's expertise in transforming scientific and technological achievements into commercialization under Gilead's umbrella.
Central to this acquisition is Stapokibart, a high-efficient, humanized antibody targeting the interleukin-4 receptor alpha subunit (IL-4Rα). Stapokibart is notable as the first domestically manufactured IL-4Rα antibody drug granted marketing approval by the NMPA. By blocking both interleukin-4 (IL-4) and interleukin-13 (IL-13) signaling, two key cytokines that trigger type II inflammation, Stapokibart has demonstrated encouraging efficacy and good safety in clinical trials. Its treatment for moderate-to-severe atopic dermatitis in adults was approved in September 2024, followed by chronic rhinosinusitis with nasal polyposis in December 2024, and Seasonal Allergic Rhinitis in February 2025.
This acquisition strategically enhances Gilead's portfolio, particularly in the immunology and inflammatory disease areas. The integration of Keymed's innovative pipeline and scientific talent with Gilead's extensive resources and global development and commercial capabilities is anticipated to create significant synergies. This combination is expected to accelerate the development and broader availability of advanced therapeutic options.
The combined entity is poised to deliver innovative treatments to a wider patient population, addressing critical unmet needs in immunology and expanding access to high-quality therapies globally.